{"id":5424,"date":"2025-12-29T12:10:36","date_gmt":"2025-12-29T12:10:36","guid":{"rendered":"https:\/\/network.rvrising.com\/?p=5424"},"modified":"2025-12-29T12:10:36","modified_gmt":"2025-12-29T12:10:36","slug":"nuvalent-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.rvrising.com\/news\/business\/nuvalent-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<p><span class=\"legendSpanClass\">CAMBRIDGE, Mass.<\/span>, <span class=\"legendSpanClass\">Dec. 22, 2025<\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"https:\/\/www.nuvalent.com\/\" target=\"_blank\" rel=\"nofollow noopener\">Nuvalent, Inc.<\/a>\u00a0(Nasdaq: <a class=\"ticket-symbol\" href=\"#financial-modal\" data-toggle=\"modal\">NUVL<\/a>), a clinical-stage biopharmaceutical company focused on creating\u00a0<i>precisely<\/i>\u00a0targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 44<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference on\u00a0Tuesday, January 13, 2026, at\u00a09:00 a.m. PT\u00a0in San Francisco.<\/p>\n<div>\n<p>A live webcast will be available in the Investors section of the company&#8217;s website at\u00a0<a href=\"http:\/\/www.nuvalent.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.nuvalent.com<\/a>, and archived for 30 days following the presentation.<\/p>\n<p><b>About Nuvalent<br class=\"dnr\" \/><\/b>Nuvalent, Inc. (Nasdaq: <a class=\"ticket-symbol\" href=\"#financial-modal\" data-toggle=\"modal\">NUVL<\/a>) is a clinical-stage biopharmaceutical company focused on creating\u00a0<i>precisely<\/i>\u00a0targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.<\/p>\n<p>SOURCE Nuvalent, Inc.<\/p>\n<\/div>\n<p><b>This release is auto-published via PR Newswire; our journal is not responsible for the content.<\/b><\/p>\n<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/nuvalent-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302647193.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Dec. 22, 2025 \/PRNewswire\/ &#8212;\u00a0Nuvalent, Inc.\u00a0(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating\u00a0precisely\u00a0targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on\u00a0Tuesday, January 13, 2026, at\u00a09:00 a.m. PT\u00a0in San Francisco. A live webcast [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5425,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,92],"tags":[],"class_list":["post-5424","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-pr-newswire"],"_links":{"self":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/5424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/comments?post=5424"}],"version-history":[{"count":1,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/5424\/revisions"}],"predecessor-version":[{"id":5560,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/5424\/revisions\/5560"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media\/5425"}],"wp:attachment":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media?parent=5424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/categories?post=5424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/tags?post=5424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}